IBA - On track for a much better H2
IBA published its Q3 trading update. Main point of attention was of course the progress made in the shipment/installation of the 8 systems planned for 2023. 2 systems have been installed and 2 have been shipped. Management reiterates that 6 systems are “under control” and mentions a return to profitability in Q3 23 with a slightly positive REBIT. Overall positive REBIT anticipated for H2 23, supported by strong acceleration in backlog conversion in Q3, which is foreseen to continue into Q4 23. OA is progressing in the right direction although remaining below 2022 levels, as expected, keeping in mind thatIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.